Journal of nanobiotechnology · 2026
Self-fueling catalysis-driven membrane destabilization triggers CSC-enriched tumors ablation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Huang Lin, Hu Basheng, Wu Guochao, Ma Wenjie, Qiu Jiaoyang, Zhu Jiaoyang, Yang Jing, Cai Haobin, Fan Qingdeng, Ren Bin, Chen Chunmei, Wang Zehui, Feng Jie, Li Yitong, Yang Sugeun, Yan Chenggong, Yu Xiangrong, Liu Zhigang, Shen Zheyu
Аннотация
Eradication of cancer stem cells (CSC) enriched tumors remains a formidable challenge due to their intrinsic drug resistance and robust cholesterol-driven anti-ferroptotic defenses. Herein, we report a cholesterol oxidase (COD)-loaded hollow mesoporous zinc-copper sulfide (COD@HMZCS-HA) nanomedicine designed to eliminate CSC via self-fueling catalysis-driven membrane destabilization. After targeted tumor accumulation, the released components function synergistically to overcome therapeutic resistance. Specifically, COD-mediated cholesterol depletion acts as an indispensable sensitizing step by dismantling the biophysical membrane barrier of protective lipid rafts and inactivating the 7-dehydrocholesterol (7-DHC)-mediated endogenous "molecular brake" on LPO. Concurrently, a self-fueling catalytic cycle, involving Cu+-mediated •OH generation, Zn2+-induced •O2⁻ accumulation and H2S-triggered hypoxia relief and intracellular acidification, drove the massive amplification and propagation of lethal LPO storm. Through simultaneous sustainment of local oxygen availability and abrogation of cholesterol-dependent membrane defenses, COD@HMZCS-HA effectively bypasses classical resistance pathways, culminating in irreversible CSC ferroptosis. In vitro and in vivo studies demonstrate that the COD@HMZCS-HA shows potent antitumor and antimetastatic efficacy due to the extensive ablation of CSC coupled with the disruption of invasive lipid rafts. Collectively, the developed self-fueling catalysis strategy simultaneously overcomes the hypoxic TME barrier and disrupts cholesterol-dependent anti-ferroptotic defenses, offering a promising therapeutic paradigm for elimination of CSC-enriched tumors.